CHADS-VASc Score Calculator for Stroke Risk Assessment

About

The CHADS-VASc score represents a refinement of the earlier CHADS2 score, developed by Lip et al. and published in Chest in 2010 to address the limitations of its predecessor in stratifying stroke risk among patients with atrial fibrillation (AF). The original validation cohort included data from 1,084 patients in the Euro Heart Survey on AF, demonstrating improved predictive accuracy for thromboembolic events compared to the CHADS2 score. By incorporating three additional risk factors — vascular disease (prior myocardial infarction, peripheral arterial disease, or aortic plaque), age 65-74 years (scoring 1 point versus 2 for age ≥75), and female sex — the CHADS-VASc score provides more granular risk discrimination, particularly for patients previously classified as low-risk (CHADS2 score of 0-1). Current guidelines from the American Heart Association, American College of Cardiology, European Society of Cardiology, and the UK National Institute for Health and Care Excellence universally endorse CHADS-VASc as the preferred initial risk stratification tool for guiding anticoagulation decisions in non-valvular AF. The score has undergone extensive external validation across diverse populations including Asian, European, and North American cohorts, with consistent c-statistics ranging from 0.70 to 0.78 for predicting ischemic stroke. Its evidence level is Grade A, supported by multiple large-scale prospective cohort studies and randomized trial data.

Formula

CHF (1) + Hypertension (1) + Age ≥75 (2) / 65-74 (1) + Diabetes (1) + Stroke/TIA (2) + Vascular Disease (1) + Age 65-74 (1) + Female Sex (1)

The CHADS-VASc score assigns points based on the presence of specific clinical risk factors, each independently weighted. Congestive heart failure (signs or symptoms of heart failure or documented LVEF ≤40%) contributes 1 point. Hypertension (resting blood pressure >140/90 mmHg or current antihypertensive therapy) contributes 1 point. Age is stratified into two categories: age ≥75 years contributes 2 points, while age 65-74 years contributes 1 point, reflecting the graduated nature of stroke risk with advancing age. Diabetes mellitus (fasting glucose ≥126 mg/dL or ongoing antidiabetic treatment) adds 1 point. Prior stroke, transient ischemic attack, or systemic thromboembolism carries the highest weight at 2 points, given its strong independent association with recurrent events. Vascular disease — encompassing prior myocardial infarction, peripheral artery disease, or angiographically documented aortic plaque — contributes 1 point. Female sex contributes 1 point. The maximum possible score is 9, with higher scores indicating proportionally greater annual stroke risk. Interpretation follows a risk-stratified approach: a score of 0 corresponds to an annual stroke risk of approximately 0.2% without anticoagulation, whereas a score of 6 or more carries an annual risk exceeding 6.7%, warranting strong consideration of oral anticoagulation.

Score Interpretation

The CHADS-VASc score is the cornerstone of stroke risk assessment in atrial fibrillation management, endorsed by the 2024 AHA/ACC Guideline for the Management of Patients With Atrial Fibrillation, the 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation, and the NICE Guideline NG196. Its primary clinical impact lies in identifying truly low-risk patients (score 0 in men, 1 in women) who can safely forgo anticoagulation, thereby avoiding the cost, inconvenience, and bleeding risk of unnecessary therapy. For patients with scores ≥1 in men and ≥2 in women, the net clinical benefit of oral anticoagulation almost uniformly favors treatment, with DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) preferred over warfarin for non-valvular AF due to their superior safety and efficacy profiles. The score predicts not only ischemic stroke but also systemic thromboembolism, and it correlates with all-cause mortality in AF populations. Importantly, the CHADS-VASc score should be complemented by bleeding risk assessment using the HAS-BLED score before initiating anticoagulation, and the two scores together form the standard framework for shared decision-making in AF. The score has also been incorporated into quality metrics for AF care, with documentation of CHADS-VASc score considered a performance measure for appropriate anticoagulation stewardship. Its widespread adoption has contributed to improved anticoagulation rates and reduced stroke incidence in AF patients globally.

Reference Ranges